Research progress on prostate-specific membrane antigen ligand positron emission tomography imaging of prostate cancer.
10.7507/1001-5515.202112035
- Author:
Yuqin LI
1
;
Bin LIU
1
;
Yongxin YUAN
2
;
Wei QIN
1
Author Information
1. Department of Nuclear Medicine, Suining Central Hospital, Suining, Sichuan 629000, P. R. China.
2. Department of Anorectal, Suining Central Hospital, Suining, Sichuan 629000, P. R. China.
- Publication Type:Journal Article
- Keywords:
Biochemical recurrence;
Positron emission tomography;
Prostate cancer;
Prostate specific membrane antigen
- MeSH:
Male;
Humans;
Prostate/pathology*;
Ligands;
Positron Emission Tomography Computed Tomography/methods*;
Prostatic Neoplasms/diagnostic imaging*;
Positron-Emission Tomography
- From:
Journal of Biomedical Engineering
2022;39(6):1263-1268
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is the most common malignant tumor in male urinary system, and the morbidity and mortality rate are increasing year by year. Traditional imaging examinations have some limitations in the diagnosis of prostate cancer, and the advent of molecular imaging probes and imaging technology have provided new ideas for the integration of diagnosis and treatment of prostate cancer. In recent years, prostate-specific membrane antigen (PSMA) has attracted much attention as a target for imaging and treatment of prostate cancer. PSMA ligand positron emission tomography (PET) has important reference value in the diagnosis, initial staging, detection of biochemical recurrence and metastasis, clinical decision-making guidance and efficacy evaluation of prostate cancer. This article briefly reviews the clinical research and application progress on PSMA ligand PET imaging in prostate cancer in recent years, so as to raise the efficiency of clinical applications.
